Source: Journal of Hepatology. Conference titles: Annual Meeting of the European Association for Study of the liver (EASL2003. Unidade: FMRP
Assunto: HEPATOPATIAS (TRATAMENTO)
ABNT
PARISE, E. et al. Prospective evaluation of Peginterferon alfa-2A (40KD)-Ribavirin in CHC, IFN/Ribavirin nonresponders/relapsers. Journal of Hepatology. Amsterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 19 abr. 2024. , 2003APA
Parise, E., Meirelles, A., Martinelli, A. de L. C., Lacet, C., Corrêa, E., Cotrim, H., et al. (2003). Prospective evaluation of Peginterferon alfa-2A (40KD)-Ribavirin in CHC, IFN/Ribavirin nonresponders/relapsers. Journal of Hepatology. Amsterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.NLM
Parise E, Meirelles A, Martinelli A de LC, Lacet C, Corrêa E, Cotrim H, Sette H, Cheinquer H, Gallizi J, Fonseca J, Paraná R, Silva R, Spinelli V, Gomes A, Crespo D, Lima L, Pereira L, Teixeira R, Amorim W, Tatsch F. Prospective evaluation of Peginterferon alfa-2A (40KD)-Ribavirin in CHC, IFN/Ribavirin nonresponders/relapsers. Journal of Hepatology. 2003 ; 38 161.[citado 2024 abr. 19 ]Vancouver
Parise E, Meirelles A, Martinelli A de LC, Lacet C, Corrêa E, Cotrim H, Sette H, Cheinquer H, Gallizi J, Fonseca J, Paraná R, Silva R, Spinelli V, Gomes A, Crespo D, Lima L, Pereira L, Teixeira R, Amorim W, Tatsch F. Prospective evaluation of Peginterferon alfa-2A (40KD)-Ribavirin in CHC, IFN/Ribavirin nonresponders/relapsers. Journal of Hepatology. 2003 ; 38 161.[citado 2024 abr. 19 ]